What is the step‑by‑step inpatient management plan for a child‑bearing‑age female patient with suspected lupus nephritis presenting with orthopnea and fluid overload?

Step-by-Step Inpatient Management for Suspected Lupus Nephritis with Orthopnea and Fluid Overload

For a child-bearing-age female with suspected lupus nephritis presenting with orthopnea and fluid overload, immediately address volume overload with diuretics and fluid restriction, confirm the diagnosis with kidney biopsy, and initiate pregnancy-safe immunosuppression if the diagnosis is confirmed while ensuring contraception counseling and avoiding teratogenic medications 1.

---

Step 1: Immediate Stabilization and Volume Management

Address the acute fluid overload first:

• Initiate loop diuretics (furosemide) to manage orthopnea and pulmonary edema
• Strict fluid restriction (typically 1-1.5L/day depending on urine output)
• Daily weights and strict intake/output monitoring
• Consider ultrafiltration or dialysis if refractory to diuretics or if uremia is present

---

Step 2: Diagnostic Confirmation

Obtain kidney biopsy to confirm lupus nephritis and determine histologic class:

• Biopsy is essential to guide therapy—do not delay if coagulation parameters are acceptable
• Send tissue for light microscopy, immunofluorescence, and electron microscopy
• Assess for concurrent thrombotic microangiopathy (TMA), which changes management 1

Concurrent laboratory evaluation:

• Urine protein-to-creatinine ratio (UPCR) or 24-hour urine protein
• Serum creatinine and eGFR
• Complement levels (C3, C4)—low levels predict higher flare risk during pregnancy 1, 2
• Anti-dsDNA antibodies—elevated titers predict higher flare risk 1, 2
• Complete blood count with differential
• ADAMTS13 activity and antiphospholipid antibodies (aPLA) to evaluate for TMA 1
• Pregnancy test (mandatory in child-bearing-age females)

---

Step 3: Rule Out Thrombotic Microangiopathy

If TMA is suspected (thrombocytopenia, hemolytic anemia, elevated LDH):

• Test ADAMTS13 activity and aPLA immediately 1
• Calculate PLASMIC score to assess TTP risk
• If PLASMIC score >5 or high clinical suspicion: start plasma exchange and glucocorticoids immediately while awaiting ADAMTS13 results 1
• If ADAMTS13 <10%: diagnose TTP and continue plasma exchange + glucocorticoids + rituximab ± caplacizumab 1
• If aPLA positive: anticoagulate with warfarin (NOT direct oral anticoagulants) ± plasma exchange 1
• If both ADAMTS13 normal and aPLA negative: evaluate for complement-mediated TMA and consider eculizumab 1

---

Step 4: Pregnancy Status and Contraception Counseling

This is critical in child-bearing-age females:

If pregnant:

• Do NOT use mycophenolate mofetil (MMF) or cyclophosphamide—both are teratogenic/toxic 1, 3, 4
• Safe immunosuppression options: glucocorticoids + azathioprine and/or tacrolimus 1, 2
• Continue hydroxychloroquine—it reduces preterm birth and intrauterine growth restriction 1, 2
• Start low-dose aspirin (≤100 mg/day) before 16 weeks gestation to reduce preeclampsia risk 1, 2
• If on MMF maintenance therapy, switch immediately to azathioprine 1

If not pregnant:

• Counsel to avoid pregnancy for ≥6 months after achieving remission 1, 2
• Discuss contraception immediately—avoid estrogen-containing contraceptives due to thrombosis risk in SLE, especially with positive aPLA 2
• Progesterone-only methods must be weighed against thrombosis risk if aPLA positive 2
• Document contraception plan before starting teratogenic medications

---

Step 5: Initiate Immunosuppressive Therapy

Treatment depends on pregnancy status and biopsy class:

If NOT Pregnant (Class III or IV Lupus Nephritis):

Induction therapy (choose based on local availability and patient factors):

• Mycophenolate mofetil (MMF) 2-3 g/day in divided doses OR mycophenolic acid equivalent
• PLUS glucocorticoids: methylprednisolone 250-500 mg IV daily × 3 days, then prednisone 0.5-1 mg/kg/day (max 60 mg/day) with rapid taper 1, 5
• Consider adding belimumab or voclosporin for triple therapy in severe cases 5, 6, 7, 8
• Alternative: cyclophosphamide (Euro-Lupus low-dose regimen: 500 mg IV every 2 weeks × 6 doses) if MMF unavailable

Hydroxychloroquine 200-400 mg/day is mandatory for all patients 1, 2, 5

If Pregnant (Active Lupus Nephritis):

Safe induction options:

• Glucocorticoids (methylprednisolone pulse followed by oral prednisone)
• PLUS azathioprine (up to 2 mg/kg/day) and/or tacrolimus (target trough 4-8 ng/mL) 1, 2, 3, 4
• Continue hydroxychloroquine 1, 2
• Low-dose aspirin ≤100 mg/day 1, 2

Critical pitfall: First-trimester glucocorticoids increase risk of gestational diabetes and cleft palate—use lowest effective dose 1

---

Step 6: Adjunctive Renoprotective Therapy

Start ACE inhibitor or ARB for proteinuria control:

• Target blood pressure <130/80 mmHg
• Aim for UPCR <0.5 g/g for complete remission 5, 6
• Monitor potassium and creatinine closely

Additional supportive care:

• Calcium and vitamin D supplementation (especially with glucocorticoid use)
• Folic acid supplementation
• Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole) if on high-dose glucocorticoids + immunosuppression
• Bone density monitoring and bisphosphonates if indicated

---

Step 7: Monitoring and Response Assessment

Tight monitoring protocol:

• Weekly labs initially: CBC, creatinine, UPCR, albumin
• Monthly complement levels (C3, C4) and anti-dsDNA
• Assess response at 3,6, and 12 months

Response definitions:

• Complete response: UPCR <0.5 g/g, normal/stable creatinine, inactive sediment
• Partial response: ≥50% reduction in proteinuria, stable creatinine
• No response: <50% reduction in proteinuria or worsening creatinine

If inadequate response at 3-6 months: switch to alternative induction agent or add third agent (belimumab, voclosporin, or rituximab) 5, 6, 7, 8

---

Step 8: Transition to Maintenance Therapy

Once remission achieved (typically 6-12 months):

• Continue MMF at lower dose (1-2 g/day) OR azathioprine 2 mg/kg/day
• Taper glucocorticoids to ≤5 mg/day prednisone or discontinue if possible 5, 6, 8
• Continue hydroxychloroquine indefinitely 1, 2
• Maintain ACE inhibitor/ARB for renoprotection

If planning pregnancy after remission:

• Ensure disease inactive for ≥6 months 1, 2
• Switch from MMF to azathioprine at least 6 weeks before conception 1
• Continue hydroxychloroquine and plan for low-dose aspirin in early pregnancy 1, 2

---

Key Pitfalls to Avoid

1. Starting MMF or cyclophosphamide without confirming pregnancy status—both are contraindicated in pregnancy 1, 3, 4
2. Delaying biopsy—histologic class determines therapy and prognosis
3. Missing concurrent TMA—requires different management (plasma exchange, anticoagulation) 1
4. Using direct oral anticoagulants for aPLA-positive patients—warfarin is superior 1
5. Stopping hydroxychloroquine—associated with increased flare risk, especially in pregnancy 1, 2
6. Inadequate contraception counseling—must avoid estrogen-containing methods 2
7. Prolonged high-dose glucocorticoids—aim for rapid taper to minimize toxicity 5, 6, 8